Cantargia (OM:CANTA) - Cours de l'action, nouvelles et analyse

CANTA Aperçu des actions

Cantargia AB (publ), une société de biotechnologie, développe des traitements à base d'anticorps pour les maladies mortelles. Plus de détails

CANTA analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 50.11% par an

Analyse des risques

Réalise moins d'un million de dollars de revenus ( SEK0 )

Cours de l'action très volatil au cours des 3 derniers mois

Les bénéfices devraient diminuer en moyenne de 3.4% par an au cours des 3 prochaines années

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

+ 1 plus de risques

Cantargia AB (publ) Concurrents

Alzinova

OM:ALZ

SEK 331.7m

Oncopeptides

OM:ONCO

SEK 330.5m

Saniona

OM:SANION

SEK 325.0m

Curasight

NGM:CURAS

DKK 225.4m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Cantargia
Historique des cours de bourse
Prix actuel de l'action	SEK 1.81
Plus haut sur 52 semaines	SEK 5.20
Plus bas sur 52 semaines	SEK 1.80
Bêta	1.74
1Variation sur 1 mois	-39.52%
Variation sur 3 mois	-54.65%
Variation sur 1 an	-51.52%
3Variation sur 3 ans	-90.26%
Variation sur 5 ans	-88.58%
Évolution depuis l'introduction en bourse	-79.87%

Nouvelles et mises à jour récentes

Recent updates

An Intrinsic Calculation For Cantargia AB (publ) (STO:CANTA) Suggests It's 47% Undervalued

May 31

Here's Why We're Not Too Worried About Cantargia's (STO:CANTA) Cash Burn Situation

May 02

Is Cantargia (STO:CANTA) In A Good Position To Invest In Growth?

Jan 10

Rendement pour les actionnaires

	CANTA	SE Biotechs	SE Marché
7D	-4.6%	-0.5%	-0.2%
1Y	-51.5%	14.3%	11.8%

Rendement vs Industrie: CANTA a sous-performé le secteur Swedish Biotechs qui a rapporté 14.3 % au cours de l'année écoulée.

Rendement vs marché: CANTA a sous-performé le marché Swedish qui a rapporté 11.8 % au cours de l'année écoulée.

Volatilité des prix

Is CANTA's price volatile compared to industry and market?
CANTA volatility
CANTA Average Weekly Movement	13.3%
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Cours de l'action stable: Le cours de l'action de CANTA a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de CANTA ( 13% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de Swedish.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2009	21	Goran Forsberg	cantargia.com

Cantargia AB (publ), une société de biotechnologie, développe des traitements à base d'anticorps pour les maladies mortelles. La société développe CAN04 (nadunolimab), un anticorps liant la protéine accessoire du récepteur de l'interleukine-1 (IL1RAP), qui est en essai clinique de phase II pour le traitement du cancer du pancréas, du cancer du poumon non à petites cellules et du cancer du sein triple négatif ; et CAN10, un anticorps contre l'IL1RAP, qui est en phase préclinique pour le traitement des maladies auto-immunes et inflammatoires, y compris la sclérose systémique et la myocardite. Elle développe également CANxx, une plateforme d'anticorps basée sur l'IL1RAP.

Cantargia AB (publ) Résumé des fondamentaux

Comment les bénéfices et les revenus de Cantargia se comparent-ils à sa capitalisation boursière ?
CANTA statistiques fondamentales
Capitalisation boursière	SEK 332.84m
Bénéfices(TTM)	-SEK 193.53m
Recettes(TTM)	n/a

0.0x

Ratio P/S

-1.7x

Ratio P/E

Le site CANTA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
CANTA compte de résultat (TTM)
Recettes	SEK 0
Coût des recettes	SEK 0
Marge brute	SEK 0
Autres dépenses	SEK 193.53m
Les revenus	-SEK 193.53m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

Feb 21, 2025

Résultat par action (EPS)	-1.05
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de CANTA?

Voir les performances historiques et les comparaisons

CANTA Aperçu des actions

Récompenses

Analyse des risques

Cantargia AB (publ) Concurrents

OM:ALZ

SEK 331.7m

OM:ONCO

SEK 330.5m

OM:SANION

SEK 325.0m

NGM:CURAS

DKK 225.4m

Historique des prix et performances

Nouvelles et mises à jour récentes

Price target decreased by 24% to kr9.67

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

New major risk - Share price stability

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Recent updates

Price target decreased by 24% to kr9.67

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

New major risk - Share price stability

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Can Cantargia (STO:CANTA) Afford To Invest In Growth?

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

We're A Little Worried About Cantargia's (STO:CANTA) Cash Burn Rate

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

New minor risk - Share price stability

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Price target decreased by 7.3% to kr12.67

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Chief Executive Officer recently bought kr104k worth of stock

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

Chief Executive Officer recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

New major risk - Financial position

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

New minor risk - Share price stability

Is Cantargia (STO:CANTA) In A Good Position To Deliver On Growth Plans?

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

We Think Cantargia (STO:CANTA) Can Afford To Drive Business Growth

Cantargia Appoints Patrik Renblad as Chief Financial Officer